Ascentage Pharma, a global biopharmaceutical leader, has released its 2022 interim results, showcasing significant advancements in the commercialization of its flagship drug, olverembatinib, for chronic myeloid leukemia (CML). Since its approval in late 2021, olverembatinib has generated impressive sales, contributing to a revenue surge of 636.9% for the first half of 2022, reaching RMB95.76 million. The company reported steady cash flow, with balances of RMB1,698 million as of June 30, 2022.

Olverembatinib, the first approved treatment for CML patients harboring the T315I mutation in China, continues to expand its reach. The drug has been included in 34 government-backed insurance programs across 10 provinces and integrated into clinical guidelines. The company’s collaboration with Innovent Biologics further strengthens its commercialization efforts in China.

Globally, Ascentage Pharma launched a Named Patient Program (NPP) in partnership with Tanner Pharma, allowing access to olverembatinib in over 130 countries where it is not yet commercially available. Additionally, the company is advancing clinical trials for olverembatinib in Canada and the U.S. and exploring its potential to treat gastrointestinal stromal tumors (GIST) and even moderate to severe COVID-19 infections.

Ascentage Pharma’s research and development efforts have intensified, with increased investment and the initiation of new clinical studies. The company now holds 205 issued patents globally and continues to make strides in novel therapeutic areas, including its promising EED protein inhibitor, APG-5918.

As a pioneer in global biopharmaceutical innovation, Ascentage Pharma’s achievements are underscored by multiple designations from the U.S. FDA, including Fast-Track and Orphan Drug statuses